AQSTHealthcare · Drug Manufacturers - Specialty & GenericThe 9 Wall Street analysts covering Aquestive Therapeutics, Inc. hold a median 12-month price target of $10 — +115.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Aquestive Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (90): Sales and profits are climbing, and climbing faster than before.
Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AQST, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +115.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Nov 2025 | Piper Sandler | Maintains | Overweight | $5.00 → $8.00 |
| 9 Oct 2025 | JMP Securities | Maintains | Market Outperform | — |
| 8 Sept 2025 | Oppenheimer | Maintains | Outperform | — |
| 17 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 June 2025 | Oppenheimer | Assumes | Outperform | $15 → $7.00 |
| 15 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2025 | Lake Street | Maintains | Buy | — |
| 20 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Dec 2024 | Cantor Fitzgerald | Initiates | Overweight | — |
| 11 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Oct 2024 | Leerink Partners | Maintains | Outperform | — |
| 8 Oct 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 30 Sept 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 Sept 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 30 Sept 2024 | Leerink Partners | Reiterates | Outperform | — |
| 14 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AQST appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 14% of US stocks
Cheaper than 98% of US stocks
Cheaper than 84% of US stocks
Higher than 82% of US stocks
Higher than 79% of US stocks
Higher than 88% of US stocks
Higher than 16% of US stocks
Higher than 4% of US stocks
Higher than 99% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Aquestive Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Aquestive Therapeutics, Inc. (AQST) held its Q2 2026 earnings call, with a transcript of the call published by Seeking Alpha. The item reports the occurrence of the company's second-quarter 2026 earnings call.
Why it matters — An AQST watcher would turn to this transcript for management's commentary on the company's quarterly results and outlook.
Aquestive Therapeutics said it plans to resubmit its new drug application for Anaphylm, its epinephrine sublingual film candidate for anaphylaxis, before the end of the third quarter. The resubmission follows completion of studies requested by the U.S. Food and Drug Administration.
Why it matters — Progress toward resubmitting Anaphylm's new drug application is a key regulatory milestone for AQST investors monitoring the product's path to potential approval.
Aquestive Therapeutics reported a second-quarter loss of $0.18 per share, wider than the Zacks Consensus Estimate of a $0.10 loss and wider than the $0.14 loss a year earlier. The headline notes the company topped revenue estimates.
Why it matters — AQST watchers would note that the quarterly loss came in worse than both analyst expectations and the prior-year period.
Aquestive Therapeutics, Inc. announced its financial results for the second quarter ended June 30, 2026, and provided a strategic business update. The announcement was made on Aug. 11, 2026.
Why it matters — The financial results and business update offer AQST watchers an official snapshot of the company's recent quarterly performance and strategic direction.
Aquestive Therapeutics announced positive findings from human factors and pharmacokinetic validation studies for its Anaphylm (dibutepinephrine) sublingual film, a severe allergy treatment, in preparation for an FDA resubmission.
Why it matters — Aquestive watchers would care because positive validation study results represent progress in the regulatory path toward resubmitting Anaphylm to the FDA.
The 9 Wall Street analysts covering Aquestive Therapeutics, Inc. have a median 12-month price target of $10, with estimates ranging from $6 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Aquestive Therapeutics, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aquestive Therapeutics, Inc. 50 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Aquestive Therapeutics, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (90 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +115.1% from the last close, and Ticker Nerd's factor model ranks Aquestive Therapeutics, Inc. 50 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Aquestive Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AQST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $11 over the next 12 months.
Aquestive Therapeutics, Inc. returned +18.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Aquestive Therapeutics Inc. is a pharmaceutical company specializing in proprietary drug delivery technologies to advance orally administered medicines.
The most recent item we track (Seeking Alpha, 12 Aug 2026): "Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call Transcript". Aquestive Therapeutics, Inc. (AQST) held its Q2 2026 earnings call, with a transcript of the call published by Seeking Alpha. The item reports the occurrence of the company's second-quarter 2026 earnings call.
Aquestive Therapeutics Inc. is a pharmaceutical company specializing in proprietary drug delivery technologies to advance orally administered medicines. It develops products that deliver complex molecules, offering non-invasive alternatives to traditional invasive therapies like injections. The company manufactures and exclusively supplies four commercialized products marketed by licensees in the United States and internationally, including Suboxone® Sublingual Film, Sympazan® Oral Film, Ondif® Oral Film, and royalty-based products such as Azstarys®. Aquestive Therapeutics Inc. leverages its PharmFilm® platform in collaborations with pharmaceutical partners to develop and commercialize new molecules. Its pipeline features late-stage Anaphylm™ (dibutepinephrine) Sublingual Film for treating severe allergic reactions like anaphylaxis, part of the AdrenaVerse™ epinephrine prodrug platform, alongside AQST-108 topical gel for dermatologic conditions and Libervant® (diazepam) Buccal Film for acute seizure clusters in epilepsy patients. Operating in the medicinal manufacturing sector, Aquestive Therapeutics Inc. emphasizes patient-friendly formats that dissolve quickly without water, enhancing accessibility for allergy and neurology treatments.
CEO Mr. Daniel Barber · 147 employees · United States · https://www.aquestive.com